In 2023, the cholesterol monitors market is anticipated to be valued at USD 2,660.3 million. The cholesterol monitors industry is expected to expand at a 7.3% CAGR from 2023 to 2033 and is likely to generate USD 5,379.2 million.
Rising rates of obesity and an aging population in developed nations like the United States, Germany, and France have increased the cases of patients with high levels of bad cholesterol, necessitating a daily rise in the need for cholesterol monitoring kits worldwide.
The global cholesterol monitor market is likely to expand due to the rising popularity of non-invasive technologies for cholesterol monitoring.
Statistical Estimation in the Global Cholesterol Monitors Market
| Attribute | Cholesterol Monitors Industry (From 2018 to 2022) |
|---|---|
| CAGR | 4.8% |
| Market Size - 2018 | USD 2084.61 million |
| Market Size - 2022 | USD 2514.6 million |
| Attribute | Cholesterol Monitors Industry (From 2023 to 2033) |
|---|---|
| CAGR | 7.3% |
| Market Size - 2023 | USD 2660.3 million |
| Market Size - 2033 | USD 5,379.2 million |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The increasing prevalence of cardiovascular disorders, coupled with a growing emphasis on early diagnosis and miniaturization of cholesterol monitors, is expected to drive the growth of the global cholesterol monitors market. The preference for self-monitoring to enhance the quality of life and lead a healthy lifestyle is another factor driving the expansion of the market.
The market is likely to expand due to the increased focus on reducing the burden of cardiovascular diseases (CVDs) worldwide and initiatives for preventive healthcare practices like screening and health check-up programs.
The development of the global cholesterol monitors market is also aided by governmental changes that provide state-of-the-art healthcare facilities and awareness campaigns that are likely to raise the standard of testing.
The absence of awareness regarding health benefits linked with lipid testing for food and beverages in emerging economies such as Bangladesh, Africa, and Afghanistan is likely to restrict the cholesterol monitors market growth throughout the forecast period.
The major factors preventing the market growth of cholesterol monitors are the need for healthcare resources, an undertrained workforce, strict safety regulations, and a lack of food safety infrastructure in the northern regions of Asia Pacific and the north and middle of Africa.
The cholesterol monitors market experienced significant growth from 2018 to 2022, driven by rising cardiovascular health awareness. Technological advancements led to more accurate and user-friendly devices, fostering market expansion.
The period from 2023 to 2033 is anticipated to witness a booming era for cholesterol monitors. Innovations like portable, connected devices and personalized health management solutions may force sustained market growth. Increasing adoption of preventive healthcare, coupled with a growing aging population, may fuel demand. Regulatory support and emphasis on telehealth services may propel market expansion for cholesterol monitors.
Integrating artificial intelligence and data analytics into cholesterol monitoring systems to revolutionize patient care. The market's transformation beyond growth can be characterized by enhanced accessibility, precision, and integration within broader healthcare ecosystems.
| Category | Product Type |
|---|---|
| Leading Segment | Single-Sided COD |
| Segment Share | 57.1% |
| Category | End User |
|---|---|
| Leading Segment | Medical |
| Market Share | 34.1% |
Single-sided COD (Chip-On-Flex) dominates the cholesterol monitors market due to its compelling advantages. Its simplified design streamlines manufacturing processes, reducing production costs. The single-sided configuration offers enhanced durability and reliability, appealing to manufacturers and end-users.
This leads to increased customer confidence, forcing higher sales figures. The efficient single-sided COD design allows for compact and user-friendly devices, fostering market acceptance. These factors collectively contribute to its market leadership by catering to industry demands for cost-effectiveness, reliability, and user-friendliness in cholesterol monitoring technology.
The medical sector dominates the cholesterol monitors market due to its critical role in patient care and disease management. With the rising prevalence of cardiovascular conditions and the increasing awareness of cholesterol's impact on health, medical professionals rely heavily on accurate and timely cholesterol monitoring.
Technological advancements fuel demand, enabling efficient and user-friendly devices for healthcare providers and patients. The stringent regulatory standards and the emphasis on preventive healthcare contribute to the medical sector's leadership in cholesterol monitor sales, ensuring better patient outcomes and overall population health.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
| Regions | Market CAGR (From 2023 to 2033) |
|---|---|
| China | 8.9% |
| India | 10.0% |
| United Kingdom | 5.7% |
| Australia | 4.8% |
North America dominates the global cholesterol monitors market, accounting for 35.3% in 2023. This market growth is primarily due to the rise in the incidence of CVDs, the rapidly aging population, the high preference for self-monitoring devices, and increased awareness related to the region's prevention and early diagnosis of diseases.
According to the Centers for Disease Control and Prevention, nearly 1 in 2 Americans have high cholesterol, i.e., almost 38% of American adults (total blood cholesterol ≥ 200 mg/dL).1 Too much cholesterol puts you at risk for heart disease and stroke, two leading causes of death in the United States.
Owing to the increased risk of high cholesterol and its asymptomatic nature, the need for cholesterol monitors is incessant in the region. The prevalence of heart diseases and obesity in the region is a major concern.
The United Health Foundation's annual report revealed that the obesity rate increased from 31.5% in 2021 to 30.4% in 2020 in the United States. This, in turn, the mounting preference for preventive healthcare is also anticipated to drive regional growth. Rising awareness and initiatives from the government and several healthcare organizations are expected to propel market growth.
Europe is the second-leading region, accounting for 28.3% of the cholesterol monitors market share in 2023. The region is likely to maintain its projected growth over the forecast period, revealing Future Market Insights.
Weight problems and obesity are snowballing rapidly across the European Union, with estimates of nearly 53% of adult problems and obesity was snowballing quickly across the European Union populace overweight in 2020. Obesity significantly increases the risk of chronic diseases like cardiovascular disease, type-2 diabetes, and hypertension. Along with this, it is a major cause of rising cases of bad cholesterol in the Europe region.
According to the World Health Organization, nearly 54% of European men and women, the highest percentage for any region worldwide, are affected by 'bad' cholesterol. Besides, approximately 133.3 million people in the five largest states (Germany, France, Italy, Spain, and the United Kingdom) suffer from high levels of bad cholesterol.
The government in several countries is trying to increase the testing and make certain guidelines to direct people towards awareness of bad cholesterol. Prominent cholesterol monitor manufacturers are developing novel technologies and innovative testing kits to make cholesterol level testing easier and cheaper. Owing to the factors mentioned earlier, the region offers a pool of growth prospects to the key players.
| Regions | Market CAGR (From 2023 to 2033) |
|---|---|
| United States | 30.8% |
| Germany | 6.5% |
| Japan | 5.0% |
Key cholesterol monitors manufacturers have entered into merger agreements to expand their portfolios and provide effective services that can assist in managing infectious diseases and uncontrollable cholesterol levels.
Prominent Cholesterol Monitors Manufacturers
| Company | Roche |
|---|---|
| Strategy | Merger |
| Details | In May 2021, Roche and GenMark Diagnostics entered into a merger agreement in which Roche fully acquired GenMark for USD 1.8 billion. Through the acquisition, Roche aims to expand its molecular diagnostics portfolio with GenMark’s expertise in syndromic testing. The companies believe that GenMark’sePlex systems enhance Roche’s work in managing infectious diseases and antibiotic resistance. |
| Company | Zydus Lifesciences |
|---|---|
| Strategy | Launch |
| Details | In May 2022, Zydus Lifesciences launched a Bempedoic Acid drug under the Bemdac brand to treat uncontrolled levels of bad cholesterol. |
| Company | Esperion |
|---|---|
| Strategy | FDA Approval |
| Details | In February 2020, Esperion received approval from the FDA for its cholesterol-lowering combo Nexlizet (bempedoic acid-ezetimibe) to lower LDL cholesterol in patients with high cholesterol or established atherosclerotic cardiovascular disease who have reached maximum-tolerated statin therapy. |
The market is expected to be valued at USD 2,660.3 million in 2023.
The market witnessed USD 2514.6 million in 2022.
The market for single-sided COD is expected to expand with a 57.1% share.
The market is predicted to hold an 8.9% growth rate until 2033.
The military category is expected to lead the market.
| Market Estimated Size (2022) | USD 568.1 Million |
|---|---|
| Market Size Projected (2029) | USD 786.2 Million |
| Market Value-based CAGR (2022 to 2029) | 4.8% |
Explore Diagnostic Devices Insights
View Reports
Cholesterol Monitors Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
